Treatment of Escherichia coli Bacteremia

Initial Empiric Therapy

For non-critically ill patients with community-acquired E. coli bacteremia, the American College of Emergency Physicians recommends empiric regimens including Ceftriaxone 2g IV every 24 hours + Metronidazole 500mg IV every 6 hours or Amoxicillin/clavulanate 1.2-2.2g IV every 6 hours 1
For critically ill patients with community-acquired E. coli bacteremia, the Infectious Diseases Society of America recommends empiric regimens including Meropenem 1g IV every 8 hours, especially if ESBL-producing E. coli is suspected 1
For healthcare-associated E. coli bacteremia, the Society for Healthcare Epidemiology of America recommends empiric regimens including Piperacillin/Tazobactam 4.5g IV every 6 hours or Meropenem 1g IV every 8 hours + Ampicillin 2g IV every 6 hours for patients at higher risk for multidrug-resistant organisms 1

For susceptible E. coli isolates, the American College of Physicians recommends narrowing therapy based on susceptibility testing to avoid unnecessary broad-spectrum coverage 2
For carbapenem-resistant E. coli (CRE), the European Society of Clinical Microbiology and Infectious Diseases recommends Ceftazidime-avibactam 2.5g IV every 8 hours, with alternatives including Meropenem-vaborbactam 4g IV every 8 hours or imipenem-cilastatin-relebactam 1.25g IV every 6 hours 3, 4
For polymyxin-based therapy, the Infectious Diseases Society of America recommends combination treatment, which shows lower mortality than monotherapy 4

For complicated infections, such as endocarditis or undrained abscesses, the American Heart Association recommends longer treatment courses of 2-6 weeks 2

For E. coli bacteremia secondary to urinary tract infection, the Infectious Diseases Society of America recommends treating according to susceptibility results with appropriate urinary tract penetration, and considering longer treatment duration and adequate source control for complicated cases 2
For E. coli bacteremia secondary to intra-abdominal infection, the Society of Critical Care Medicine recommends ensuring adequate source control through drainage of collections 1

The American College of Physicians recommends obtaining blood cultures before starting antibiotics to avoid suboptimal therapy 2
For enterohemorrhagic E. coli (EHEC/STEC), the Centers for Disease Control and Prevention recommends avoiding antibiotics, as they may worsen outcomes by increasing Shiga toxin production 2
Local antimicrobial susceptibility patterns should guide empiric therapy, as E. coli resistance varies considerably between regions, according to the World Health Organization 2
For critically ill patients with E. coli bacteremia, the Surviving Sepsis Campaign recommends combination therapy until susceptibility results are available 2
In patients with normal renal function, the American College of Cardiology recommends administering aminoglycosides in multiple daily divided doses rather than once daily 5

Follow-up blood cultures should be obtained 2-4 days after initial positive cultures to document clearance of bacteremia 6

The Infectious Diseases Society of America recommends avoiding ampicillin-sulbactam due to high E. coli resistance rates 7
For critically ill patients or suspected ESBL producers, alternative carbapenems such as imipenem-cilastatin or doripenem can be used 7, 8
Local antibiogram data must guide empiric choices, as recommended by the Infectious Diseases Society of America 7, 8

For ESBL-producing E. coli, the Infectious Diseases Society of America recommends continuing carbapenem therapy (meropenem, imipenem-cilastatin, or doripenem) 7, 8

For complicated infections such as persistent bacteremia at 72 hours or complications, the American College of Physicians recommends 4-6 weeks of therapy 9
For osteomyelitis, the American College of Physicians recommends 6-8 weeks of therapy 9

The Infectious Diseases Society of America recommends ensuring adequate source control, including draining collections or performing surgical intervention for intra-abdominal sources 7, 8
For catheter-related infection, the American College of Physicians recommends removing the central venous catheter if S. aureus or Candida co-infection is present, and considering salvage for E. coli alone 9

The Centers for Disease Control and Prevention recommends avoiding fluoroquinolones if local E. coli resistance exceeds 10-20% 8
The Centers for Disease Control and Prevention recommends not using antibiotics for enterohemorrhagic E. coli (EHEC/STEC) as they increase the risk of hemolytic uremic syndrome 10, 11
The Infectious Diseases Society of America recommends that enterococcal coverage is not routinely needed for community-acquired E. coli bacteremia 7, 8
The Infectious Diseases Society of America recommends that aminoglycosides are not recommended for routine use due to toxicity and availability of equally effective, less toxic alternatives 7

The Infectious Diseases Society of America recommends that higher mortality risk factors requiring aggressive therapy include an APACHE II score ≥15 8
The Infectious Diseases Society of America recommends that higher mortality risk factors requiring aggressive therapy include immunosuppression (transplant, chemotherapy, chronic steroids) 8
The American College of Physicians recommends that higher mortality risk factors requiring aggressive therapy include inadequate source control 8
The American College of Physicians recommends that higher mortality risk factors requiring aggressive therapy include persistent bacteremia beyond 72 hours 9

Re-evaluation is necessary if fever persists beyond 7 days in patients with E. coli bacteremia, with follow-up blood cultures at 2-4 days to document clearance, as recommended by the Infectious Diseases Society of America 12